Hepion Pharmaceuticals (NASDAQ:HEPA) and ProMetic Life Sciences (OTCMKTS:PFSCF) Critical Analysis
by Scott Moore · The Cerbat GemProfitability
This table compares Hepion Pharmaceuticals and ProMetic Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hepion Pharmaceuticals | N/A | -812.56% | -207.31% |
| ProMetic Life Sciences | -894.02% | -3,350.55% | -67.76% |
Institutional and Insider Ownership
17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of ProMetic Life Sciences shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Hepion Pharmaceuticals and ProMetic Life Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hepion Pharmaceuticals | N/A | N/A | -$48.93 million | ($72.15) | 0.00 |
| ProMetic Life Sciences | $36.55 million | 3.49 | -$150.73 million | N/A | N/A |
Hepion Pharmaceuticals has higher earnings, but lower revenue than ProMetic Life Sciences.
Risk and Volatility
Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500.
Summary
Hepion Pharmaceuticals beats ProMetic Life Sciences on 5 of the 8 factors compared between the two stocks.
About Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
About ProMetic Life Sciences
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.